Cell Line Characterization and Cell Line Development Market

Cell Line Characterization and Cell Line Development Market (3rd Edition), Industry Trends and Forecasts till 2035: Distribution by Source of Cell Line / Expression System (Mammalian, Microbial, Insect and Others), Application of Cell Line (Research and Development, and Biomanufacturing), Company Size (Small, Mid-Sized, Large) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    617

  • Pages
    455

  • View Count
    16403

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Cell Culture
5.2.1. Classification of Cell Cultures
5.2.1.1. Classification based on Origin
5.2.1.1.1. Primary Cell Cultures
5.2.1.1.2. Secondary Cell Cultures

5.2.1.2. Classification based on Growth Properties
5.2.1.2.1. Adherent Cell Cultures
5.2.1.2.2. Suspension Cell Cultures

5.2.2. Classification of Cell Lines
5.2.2.1. Classification based on Lifespan of Cell Line
5.2.2.1.1. Finite Cell Lines
5.2.2.1.2. Continuous Cell Lines

5.2.2.2. Classification based on Type of Cell Line
5.2.2.2.1. Recombinant Cell Lines
5.2.2.2.2. Hybridoma Cell Lines

5.2.2.3. Classification based on Source of Cell Line
5.2.2.3.1. Mammalian Cell Lines
5.2.2.3.2. Non-Mammalian Cell lines

5.3. Overview of Cell Line Characterization
5.3.1. Cell Line Characterization Methods
5.3.1.1. Identity / Stability Testing
5.3.1.1.1. Karyotype Analysis
5.3.1.1.2. Cytochrome C Oxidase I Barcoding Assay
5.3.1.1.3. Cell Morphology Analysis
5.3.1.1.4. DNA Analysis

5.3.1.2. Sterility / Biosafety Testing
5.3.1.2.1. Mycoplasma Contamination Testing
5.3.1.2.2. Viral Contamination Testing

5.4. Applications of Cell Lines
5.5. Key Concerns Associated with Cell Lines
5.6. Need for Outsourcing Cell Line Related Operations
5.7. Concluding Remarks

6. CELL LINE DEVELOPMENT SERVICE PROVIDERS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Cell Line Development Service Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Source of Cell Line / Expression System Offered
6.2.6. Analysis by Gene Delivery Method Used
6.2.7. Analysis by Type of Transfection
6.2.8. Analysis by Availability of Serum-Free / Animal Component Free Culturing Capability
6.2.9. Analysis by Type of Cells Offered
6.2.10. Analysis by Application of Cell Lines
6.2.11. Analysis by Additional Cell Line Related Services Offered
6.2.12. Analysis by Type of Cell Banking
6.2.13. Analysis by Availability of Integrated Cell Line Characterization Service

7. CELL LINE DEVELOPMENT SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Cell Line Development Service Providers: Company Competitiveness Analysis
7.4.1. Cell Line Development Service Providers in North America
7.4.2. Cell Line Development Service Providers in Europe
7.4.3. Cell Line Development Service Providers in Asia-Pacific

8. COMPANY PROFILES: CELL LINE DEVELOPMENT SERVICE PROVIDERS
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Service Providers
8.2.1 ATUM
8.2.1.1. Company Overview
8.2.1.2. Cell Line Development Service Portfolio
8.2.1.3. Recent Developments and Future Outlook

8.2.2. Curia
8.2.2.1. Company Overview
8.2.2.2. Cell Line Development Service Portfolio
8.2.2.3. Recent Developments and Future Outlook

8.2.3. Fujifilm Diosynth Biotechnologies
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio for Cell Line Development
8.2.3.3. Recent Developments and Future Outlook

8.2.4. Lonza
8.2.4.1. Company Overview
8.2.4.2. Cell Line Development Service Portfolio
8.2.4.3. Recent Developments and Future Outlook

8.2.5. Syngene International
8.2.5.1. Company Overview
8.2.5.2. Cell Line Development Service Portfolio
8.2.5.3. Recent Developments and Future Outlook

8.2.6. WuXi Biologics
8.2.6.1. Company Overview
8.2.6.2. Cell Line Development Service Portfolio
8.2.6.3. Recent Developments and Future Outlook

8.3. Short Profiles of Other Prominent Service Providers

8.3.1. Biovian
8.3.1.1. Company Overview
8.3.1.2. Cell Line Development Service Portfolio

8.3.2. Celonic
8.3.2.1. Company Overview
8.3.2.2. Cell Line Development Service Portfolio

8.3.3. ChemPartner
8.3.3.1. Company Overview
8.3.3.2. Cell Line Development Service Portfolio

8.3.4. Creative Biogene
8.3.4.1. Company Overview
8.3.4.2. Cell Line Development Service Portfolio

8.3.5. KBI Biopharma
8.3.5.1. Company Overview
8.3.5.2. Cell Line Development Service Portfolio

8.3.6. Kemp Proteins
8.3.6.1. Company Overview
8.3.6.2. Cell Line Development Service Portfolio

8.3.7. KMD Bioscience
8.3.7.1. Company Overview
8.3.7.2. Cell Line Development Service Portfolio

8.3.8. Mycenax Biotech
8.3.8.1. Company Overview
8.3.8.2. Cell Line Development Service Portfolio
8.3.9. ProBioGen
8.3.9.1. Company Overview
8.3.9.2. Cell Line Development Service Portfolio

8.3.10. Thermo Fisher Scientific
8.3.10.1. Company Overview
8.3.10.2. Cell Line Development Service Portfolio

9. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Cell Line Characterization Service Providers: Overall Market Landscape
9.2.1. Cell Line Characterization Service Providers Service Providers (Industry Players)
9.2.1.1. Analysis by Year of Establishment
9.2.1.2. Analysis by Company Size
9.2.1.3. Analysis by Location of Headquarters
9.2.1.4. Analysis by Location of Headquarters and Company Size
9.2.1.5. Analysis by Cell line Characterized
9.2.1.6. Analysis by Type of Cell Line Characterization Service Offered
9.2.1.6.1. Analysis by Type of Cell Line Identity / Stability Testing Service Offered
9.2.1.6.2. Analysis by Type of Cell Line Sterility / Biosafety Testing Service Offered

9.2.2. Cell Line Characterization Service Providers (Non-Industry Players)
9.2.2.1. Analysis by Location of Organization
9.2.2.2. Analysis by Types of Cell Line Characterized
9.2.2.3. Analysis by Type of Cell Line Characterization Service Offered
9.2.2.4. Analysis by Genotyping Kit Used
9.2.2.5. Analysis by Number of Loci Amplified

10. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Methodology
10.4. Cell Line Characterization Service Providers: Company Competitiveness Analysis
10.4.1. Cell Line Characterization Service Providers in North America
10.4.2. Cell Line Characterization Service Providers in Europe
10.4.3. Cell Line Characterization Service Providers in Asia-Pacific

11. COMPANY PROFILES: CELL LINE CHARACTERIZATION SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Detailed Company Profiles of Leading Service Provider

11.3.1 Charles River Laboratories
11.3.1.1. Company Overview
11.3.12. Cell Line Characterization Service Portfolio
11.3.1.3. Recent Developments and Future Outlook

11.3.2. Eurofins BioPharma Product Testing
11.3.2.1. Company Overview
11.3.2.2. Cell Line Characterization Service Portfolio
11.3.2.3. Recent Developments and Future Outlook

11.3.3. Livogen Pharmed
11.3.3.1. Company Overview
11.3.3.2. Cell Line Characterization Service Portfolio
11.3.3.3. Recent Developments and Future Outlook

11.3.4. Molecular Diagnostic Services
11.3.4.1. Company Overview
11.3.4.2. Cell Line Characterization Service Portfolio
11.3.4.3. Recent Developments and Future Outlook

11.3.5. Sartorius
11.3.5.1. Company Overview
11.3.5.2. Cell Line Characterization Service Portfolio
11.3.5.3. Recent Developments and Future Outlook

11.3.6. TFBS Bioscience
11.3.6.1. Company Overview
11.3.6.2. Cell Line Characterization Service Portfolio
11.3.6.3. Recent Developments and Future Outlook

10.3. Short Profiles of Other Prominent Service Providers

11.3.1 ATZ Labs (Subsidiary of Life Technologies)
11.3.1.1. Company Overview
11.3.1.2. Cell Line Characterization Service Portfolio

11.3.2. Avance Biosciences
11.3.2.1. Company Overview
11.3.2.2. Cell Line Characterization Service Portfolio

11.3.3. BioReliance
11.3.3.1. Company Overview
11.3.3.2. Cell Line Characterization Service Portfolio

11.3.4. Clean Cells
11.3.4.1. Company Overview
11.3.4.2. Cell Line Characterization Service Portfolio

11.3.5. hylabs
11.3.5.1. Company Overview
11.3.5.2. Cell Line Characterization Service Portfolio

11.3.6. Samsung Biologics
11.3.6.1. Company Overview
11.3.6. Cell Line Characterization Service Portfolio

11.3.7. SGS Life Sciences
11.3.7.1. Company Overview
11.3.7.2. Cell Line Characterization Service Portfolio

11.3.8. Texcell
11.3.8.1. Company Overview
11.3.8.2. Cell Line Characterization Service Portfolio

11.3.9. WuXi Advanced Therapies
11.3.9.1. Company Overview
11.3.9.2. Cell Line Characterization Service Portfolio

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Cell Line Development and Characterization: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Partner
12.3.5. Most Active Players: Analysis by Number of Partnerships
12.3.6. Analysis by Geography
12.3.6.1. Intracontinental and Intercontinental Deals
12.3.6.2. International and Local Deals

13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Cell Line Development and Characterization: List of Recent Expansions
13.2.1. Analysis by Year of Expansion
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Year and Type of Expansion
13.2.4. Analysis by Location of Headquarters and Company Size
13.2.5. Analysis by Location of Expanded Facility
13.2.6. Analysis by Type of Expansion and Location of Expanded Facility
13.2.7. Analysis by Area of Expanded Facility (sq ft)
13.2.8. Analysis by Purpose of Expansion
13.2.9. Analysis by Geography
13.2.9. Most Active Players: Analysis by Number of Recent Expansions

14. CELL LINE REPOSITORIES
14.1. Chapter Overview
14.2. American Type Culture Collection (ATCC)
14.2.1. Overview
14.2.2. Service Portfolio

14.3. Coriell Institute for Medical Research
14.3.1. Overview
14.3.2. Service Portfolio

14.4. European Collection of Authenticated Cell Cultures (ECACC)
14.4.1. Overview
14.4.2. Service Portfolio

14.5. Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures
14.5.1. Overview
14.5.2. Service Portfolio

14.6. National Centre for Cell Science (NCCS)
14.6.1. Overview
14.6.2. Service Portfolio

15. REGULATORY RECOMMENDATIONS AND GUIDELINES
15.1. Chapter Overview
15.2. Cell Line Authentication: Prominent Regulatory Authorities
15.2.1. Role of American Type Culture Collection (ATCC)
15.2.2. Role of International Cell Line Authentication Committee (ICLAC)
15.2.3. Role of Global Biological Standards Institute (GBSI)

15.3. Guidelines Issued by International Regulatory Agencies
15.3.1. World Health Organization
15.3.2. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)

15.4. Regulatory Guidelines for Cell Line Characterization in the US
15.4.1. Food and Drug Administration
15.4.1.1. FDA Points to Consider
15.4.1.2. US Pharmacopeial Convention
15.4.1.3. US Code for Federal Regulations

15.5. Regulatory Guidelines for Cell Line Characterization in Europe
15.5.1. European Medicines Agency

15.6. Regulatory Guidelines for Cell Line Characterization In Japan
15.6.1. Ministry of Health, Labor and Welfare

15.7. Concluding Remarks

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL CELL LINE DEVELOPMENT SERVICES MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global Cell Line Development Services Market, Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario

17.4. Key Market Segmentations

18. CELL LINE DEVELOPMENT SERVICES MARKET, BY SOURCE OF CELL LINES
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cell Line Development Services Market: Distribution by Source of Cell Lines 2019, 2023 and 2035
18.3.1. Cell Line Development Services Market for Mammalian Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
18.3.2. Cell Line Development Services Market for Microbial Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
18.3.3. Cell Line Development Services Market for Insect Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
18.3.4. Cell Line Development Services Market for Other Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

18.4. Data Triangulation and Validation

19. CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION OF CELL LINES
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell Line Development Services Market: Distribution by Application Of Cell Lines 2019, 2023 and 2035
19.3.1. Cell Line Development Services Market for Biomanufacturing: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
19.3.2. Cell Line Development Services Market for Research and Development Operations: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

19.4. Data Triangulation and Validation

20. CELL LINE DEVELOPMENT SERVICES MARKET, BY COMPANY SIZE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Cell Line Development Services Market: Distribution by Company Size 2019, 2023 and 2035
20.3.1. Cell Line Development Services Market for Large Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
20.3.2. Cell Line Development Services Market for Mid-sized Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
20.3.3. Cell Line Development Services Market for Small Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

20.4. Data Triangulation and Validation

21. CELL LINE DEVELOPMENT SERVICES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Cell Line Development Services Market: Distribution by Company Size 2019, 2023 and 2035
21.3.1. Cell Line Development Services Market for North America: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
21.3.2. Cell Line Development Services Market for Europe: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
21.3.3. Cell Line Development Services Market for Asia-Pacific and Rest of the World: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

21.4. Data Triangulation and Validation

22. GLOBAL CELL LINE CHARACTERIZATION SERVICES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Cell Line Characterization Services Market, Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis
22.3.1.1. Conservative Scenario
22.3.1.2. Optimistic Scenario

22.4. Key Market Segmentations

23. CELL LINE CHARACTERIZATION SERVICES MARKET, BY SOURCE OF CELL LINES
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Cell Line Characterization Services Market: Distribution by Source of Cell Lines 2019, 2023 and 2035
23.3.1. Cell Line Characterization Services Market for Mammalian Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
23.3.2. Cell Line Characterization Services Market for Microbial Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
23.3.3. Cell Line Characterization Services Market for Insect Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
23.3.4. Cell Line Characterization Services Market for Other Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

23.4. Data Triangulation and Validation

24. CELL LINE CHARACTERIZATION SERVICES MARKET, BY APPLICATION OF CELL LINES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Cell Line Characterization Services Market: Distribution by Application Of Cell Lines 2019, 2023 and 2035
24.3.1. Cell Line Characterization Services Market for Biomanufacturing: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
24.3.2. Cell Line Characterization Services Market for Research and Development Operations: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

24.4. Data Triangulation and Validation

25. CELL LINE CHARACTERIZATION SERVICES MARKET, BY COMPANY SIZE
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Cell Line Characterization Services Market: Distribution by Company Size 2019, 2023 and 2035
25.3.1. Cell Line Characterization Services Market for Large Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
25.3.2. Cell Line Characterization Services Market for Mid-sized Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
25.3.3. Cell Line Characterization Services Market for Small Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

25.4. Data Triangulation and Validation

26. CELL LINE CHARACTERIZATION SERVICES MARKET, BY KEY GEOGRAPHICAL REGIONS
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Cell Line Characterization Services Market: Distribution by Company Size 2019, 2023 and 2035
26.3.1. Cell Line Characterization Services Market for North America: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
26.3.2. Cell Line Characterization Services Market for Europe: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)
26.3.3. Cell Line Characterization Services Market for Asia-Pacific and Rest of the World: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)

26.4. Data Triangulation and Validation

27. CONCLUDING REMARKS

28. EXECUTIVE INSIGHTS
28.1. Chapter Overview
28.2. Biofortuna
28.2.1. Company Snapshot
28.2.2. Interview Transcript: Nick Ash, Chief Executive Officer

28.3. Abgenex
28.3.1. Company Snapshot
28.3.2. Interview Transcript: Prasanta Maiti, Principal Scientist and Head, R&D

28.4. GTP Bioways
28.4.1. Company Snapshot
28.4.2. Interview Transcript: Séverine Hountondji, Director, Business Development and Marketing

28.5. Quacell Biotechnology
28.5.1. Company Snapshot
28.5.2. Interview Transcript: Fai Poon, Founder and President

28.6. Largan
28.6.1. Company Snapshot
28.6.2. Interview Transcript: Jin Liang, President

28.7. Polpharma Biologics
28.7.1. Company Snapshot
28.7.2. Interview Transcript: Louis Boon, Chief Scientific Officer

28.8. LakePharma
28.8.1. Company Snapshot
28.8.2. Interview Transcript: Fan Chen, Former Vice President BioProcessing

28.9. ARTES Biotechnology
28.9.1. Company Snapshot
28.9.2. Interview Transcript: Michael Pointek, Founder and Managing Director

28.10. ImmunoPrecise Antibodies (Formerly Known as ModiQuest)
28.10.1. Company Snapshot
28.10.2. Interview Transcript: Nienke Smits, Client Relations Manager

28.11. Polpharma Biologics (Formerly Known as Bioceros)
28.11.1. Company Snapshot
28.11.2. Interview Transcript: Oscar Hoogteijling, Former Business Development Manager

29. APPENDIX 1: TABULATED DATA

30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

31. APPENDIX 3: DETAILS OF PARTNERSHIPS AND COLLABORATIONS

List Of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Cell Line Development Service Providers Market Landscape
Figure 4.2 Executive Summary: Cell Line Characterization Service Providers Market Landscape
Figure 4.3 Executive Summary: Partnership and Collaborations
Figure 4.4 Executive Summary: Recent Expansions
Figure 4.5 Executive Summary: Cell line Development Service Providers Market Sizing and Opportunity Analysis
Figure 4.6 Executive Summary: Cell line Characterization Service Providers Market Sizing and Opportunity Analysis
Figure 5.1 Process of Cell Culturing
Figure 5.2 Initiation of Cell Cultures
Figure 5.3 Sources of Non-Mammalian Cell Lines
Figure 5.4 Karyotype Preparation: Process Workflow
Figure 5.5 DNA Hybridization: Process Workflow
Figure 5.6 DNA Fingerprinting: Process Workflow
Figure 5.7 Applications of Cell Lines
Figure 5.8 Factors Affecting the Quality of Cell Lines
Figure 5.9 Advantages and Risks Associated with Outsourcing of Cell Line Related Operations
Figure 6.1 Cell Line Development Service Providers: Distribution by Year of Establishment
Figure 6.2 Cell Line Development Service Providers: Distribution by Company Size
Figure 6.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
Figure 6.4 Cell Line Development Service Providers: Distribution by Company Size and Location of Headquarters
Figure 6.5 Cell Line Development Service Providers: Distribution by Source of Cell Line / Expression System Offered
Figure 6.6 Cell Line Development Service Providers: Distribution by Gene Delivery Method Used
Figure 6.7 Cell Line Development Service Providers: Distribution by Type of Transfection
Figure 6.8 Cell Line Development Service Providers: Distribution by Availability of Serum-Free / Animal Component Free Culturing Capability
Figure 6.9 Cell Line Development Service Providers: Distribution by Type of Cells Offered
Figure 6.10 Cell Line Development Service Providers: Distribution by Application of Cell Line
Figure 6.11 Cell Line Development Service Providers: Distribution by Additional Cell Line Related Services Offered
Figure 6.12 Cell Line Development Service Providers: Distribution by Type of Cell Banking
Figure 6.13 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
Figure 7.1 Company Competitiveness Analysis: Cell Line Development Service Providers in North America
Figure 7.2 Company Competitiveness Analysis: Cell Line Development Service Providers in Europe
Figure 7.3 Company Competitiveness Analysis: Cell Line Development Service Providers in Asia-Pacific and rest of the world
Figure 9.1 Cell Line Characterization Service Providers: Overall Market Landscape
Figure 9.2 Cell Line Characterization Service Providers (Industry): Distribution by Year of Establishment
Figure 9.3 Cell Line Characterization Service Providers (Industry): Distribution by Company Size
Figure 9.4 Cell Line Characterization Service Providers (Industry): Distribution by Location of Headquarters
Figure 9.5 Cell Line Characterization Service Providers (Industry): Distribution by Company Size and Location of Headquarters
Figure 9.6 Cell Line Characterization Service Providers (Industry): Distribution by Cell Line Characterized
Figure 9.7 Cell Line Characterization Service Providers (Industry): Distribution by Type of Cell Line Characterization Service Offered
Figure 9.8 Cell Line Characterization Service Providers (Industry): Distribution by Type of Cell Line Identity / Stability Testing Service Offered
Figure 9.9 Cell Line Characterization Service Providers (Industry): Distribution by Type of Cell Line Sterility / Biosafety Testing Service Offered
Figure 9.10 Cell Line Characterization Service Providers (Non-Industry): Distribution by Location of Organization
Figure 9.11 Cell Line Characterization Service Providers (Non-Industry): Distribution by Type of Cell Line Characterized
Figure 9.12 Cell Line Characterization Service Providers (Non-Industry): Distribution by Type of Cell Line Characterization Service Offered
Figure 9.13 Cell Line Characterization Service Providers (Non-Industry): Distribution by Genotyping Kit Used
Figure 9.14 Cell Line Characterization Service Providers (Non-Industry): Distribution by Number of Loci Amplified
Figure 10.1 Company Competitiveness Analysis: Cell Line Development Service Providers in North America
Figure 10.2 Company Competitiveness Analysis: Cell Line Development Service Providers in Europe
Figure 10.3 Company Competitiveness Analysis: Cell Line Development Service Providers in Asia-Pacific and rest of the world
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend , 2015-2023
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.5 Most Active Players: Distribution by Number of Partnerships
Figure 12.6 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 12.7 Partnerships and Collaborations: International and Local Deals
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, -2023
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 13.4 Recent Expansions: Distribution by Location of Headquarters and Company Size
Figure 13.5 Recent Expansions: Distribution by Location of Expanded Facility
Figure 13.6 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Figure 13.7 Recent Expansions: Distribution by Area of Expanded Facility (sq. ft.)
Figure 13.8 Recent Expansions: Distribution by Purpose of Expansion
Figure 13.9 Recent Expansions: Distribution by Geography
Figure 13.10 Most Active Players: Distribution by Number of Recent Expansions
Figure 14.1 American Type Culture Collection (ATCC): Service Portfolio
Figure 14.2 Coriell Institute for Medical Research: Service Portfolio
Figure 14.3 European Collection of Authenticated Cell Cultures (ECACC): Culture Collection
Figure 14.4 European Collection of Authenticated Cell Cultures (ECACC): Service Portfolio
Figure 14.5 Leibniz Institute DSMZ: Biological Material Collection
Figure 14.6 National Centre for Cell Science (NCCS): Service Portfolio
Figure 15.1 The International Council for Harmonisation Q5A (R1) Guidelines: Cell Bank Qualification
Figure 15.2 The International Council for Harmonisation Q5D Guidelines: Cell Bank Characterization
Figure 15.3 FDA Guidelines: Cell Bank Qualification
Figure 15.4 US Pharmacopoeia (USP) 63: Mycoplasma Detection in Cell Banks
Figure 15.5 Code for Federal Regulations (CFR) 610.18: Recommendations for Testing of Cell Lines
Figure 16.1 Market Drivers
Figure 16.2 Market Restrainers
Figure 16.3 Market Opportunities
Figure 16.4 Market Challenges
Figure 17.1 Global Cell Line Development Services Market, Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 17.2 Global Cell Line Development Services Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 17.3 Global Cell Line Development Services Market, 2023-2035, Conservative Scenario (USD Million)
Figure 18.1 Cell Line Development Services Market: Distribution by Source of Cell Lines 2019, 2023 and 2035
Figure 18.2 Cell Line Development Services Market for Mammalian Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 18.3 Cell Line Development Services Market for Microbial Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 18.4 Cell Line Development Services Market for Insect Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 18.5 Cell Line Development Services Market for Other Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.1 Cell Line Development Services Market: Distribution by Application of Cell Line 2019, 2023 and 2035
Figure 19.2 Cell Line Development Services Market for Biomanufacturing: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.3 Cell Line Development Services Market for Research and Development Operations: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.1 Cell Line Development Services Market: Distribution by Company Size 2019, 2023 and 2035
Figure 20.2 Cell Line Development Services Market for Large Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.3 Cell Line Development Services Market for Mid-sized Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.4 Cell Line Development Services Market for Small Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.1 Cell Line Development Services Market: Distribution by Key Geographical Regions 2019, 2023 and 2035
Figure 21.2 Cell Line Development Services Market for North America: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.3 Cell Line Development Services Market for Europe: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.4 Cell Line Development Services Market for Asia-Pacific and Rest of the World: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.1 Global Cell Line Characterization Services Market, Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.2 Global Cell Line Characterization Services Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 22.3 Global Cell Line Characterization Services Market, 2023-2035, Conservative Scenario (USD Million)
Figure 23.1 Cell Line Characterization Services Market: Distribution by Source of Cell Line 2019, 2023 and 2035
Figure 23.2 Cell Line Characterization Services Market for Mammalian Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.3 Cell Line Characterization Services Market for Microbial Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.4 Cell Line Characterization Services Market for Insect Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.5 Cell Line Characterization Services Market for Other Cell Lines: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 24.1 Cell Line Characterization Services Market: Distribution by Application of Cell Line 2019, 2023 and 2035
Figure 24.2 Cell Line Characterization Services Market for Biomanufacturing: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 24.3 Cell Line Characterization Services Market for Research and Characterization Operations: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.1 Cell Line Characterization Services Market: Distribution by Company Size 2019, 2023 and 2035
Figure 25.2 Cell Line Characterization Services Market for Large Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.3 Cell Line Characterization Services Market for Mid-sized Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.4 Cell Line Characterization Services Market for Small Companies: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 26.1 Cell Line Characterization Services Market: Distribution by Key Geographical Regions 2019, 2023 and 2035
Figure 26.2 Cell Line Characterization Services Market for North America: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 26.3 Cell Line Characterization Services Market for Europe: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 26.4 Cell Line Characterization Services Market for Asia-Pacific and Rest of the World: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 27.1 Concluding Remarks: Cell Line Development Service Providers Market Landscape
Figure 27.2 Concluding Remarks: Cell Line Characterization Service Providers Market Landscape
Figure 27.3 Concluding Remarks: Partnerships and Collaborations
Figure 27.4 Concluding Remarks: Recent Expansions
Figure 27.5 Concluding Remarks: Cell Line Development Service Providers Market Forecast and Opportunity Analysis
Figure 27.6 Concluding Remarks: Cell Line Characterization Service Providers Market Forecast and Opportunity Analysis

List Of Tables

Table 5.1 Comparison between Finite and Continuous Cell Lines
Table 5.2 Popular Mammalian Cell Lines used in Biopharmaceutical Production
Table 5.3 Human Cell Lines and Therapeutic Protein Products
Table 5.4 Cell Lines and Viral Vaccine Products
Table 6.1 Cell Line Development: List of Service Providers
Table 6.2 Cell Line Development Service Providers: Information on Source ofCell Line / Expression System Offered, Gene Delivery Method Used and Type of Transfection
Table 6.3 Cell Line Development Service Providers: Information on AvailabilitySerum free / Animal Component Free Culturing Capability, Types of Cells Offered and Applications of Cell Lines
Table 6.4 Cell Line Development Service Providers: Information on AdditionalCell Line Related Services Offered, Type of Cell Banking and Integrated Cell Line Characterization Service
Table 6.5 Cell Line Development Service Providers: Information on Technology/Cell Line / Vectors / Expression System Used (if available), Availability of Monoclonality Procedure, Availability of Biosimilar Cell Line Development Service and Availability of Genetically Edited Cell Line Development Service
Table 8.1 Cell Line Development Service Providers: List of Companies Profiled
Table 8.2 ATUM: Company Snapshot
Table 8.3 ATUM: Cell Line Development Service Portfolio
Table 8.4 ATUM: Recent Developments and Future Outlook
Table 8.5 Curia: Company Snapshot
Table 8.6 Curia: Cell Line Development Service Portfolio
Table 8.7 Curia: Recent Developments and Future Outlook
Table 8.8 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 8.9 FUJIFILM Diosynth Biotechnologies: Cell Line Development Service Portfolio
Table 8.10 FUJIFILM Diosynth Biotechnologies: Recent Developments and FutureOutlook
Table 8.11 Lonza: Company Snapshot
Table 8.12 Lonza: Cell Line Development Service Portfolio
Table 8.13 Lonza: Recent Developments and Future Outlook
Table 8.14 Syngene International: Company Snapshot
Table 8.15 Syngene International: Cell Line Development Service Portfolio
Table 8.16 Syngene International: Recent Developments and Future Outlook
Table 8.17 WuXi Biologics: Company Snapshot
Table 8.18 WuXi Biologics: Cell Line Development Service Portfolio
Table 8.19 WuXi Biologics: Recent Developments and Future Outlook
Table 8.20 Biovian: Company Snapshot
Table 8.21 Biovian: Cell Line Development Service Portfolio
Table 8.22 Celonic: Company Snapshot
Table 8.23 Celonic: Cell Line Development Service Portfolio
Table 8.24 ChemPartner: Company Snapshot
Table 8.25 ChemPartner: Cell Line Development Service Portfolio
Table 8.26 Creative Biogene: Company Snapshot
Table 8.27 Creative Biogene: Cell Line Development Service Portfolio
Table 8.28 KBI Biopharma: Company Snapshot
Table 8.29 KBI Biopharma: Cell Line Development Service Portfolio
Table 8.30 Kemp Proteins: Company Snapshot
Table 8.31 Kemp Proteins: Cell Line Development Service Portfolio
Table 8.32 KMD Bioscience: Company Snapshot
Table 8.33 KMD Bioscience: Cell Line Development Service Portfolio
Table 8.34 Mycenax Biotech: Company Snapshot
Table 8.35 Mycenax Biotech: Cell Line Development Service Portfolio
Table 8.36 ProBioGen: Company Snapshot
Table 8.37 ProBioGen: Cell Line Development Service Portfolio
Table 8.38 Thermo Fisher Scientific: Company Snapshot
Table 8.39 Thermo Fisher Scientific: Cell Line Development Service Portfolio
Table 9.1 Cell Line Characterization: List of Service Providers (Industry Players)
Table 9.2 Cell line Development Service Providers: Information on Cell Line Characterized and TypeofCellLineCharacterizationServicesOffered
Table 9.3 Cell Line Characterization Service Providers: Information on Type of Cell LineIdentity/ StabilityTestingServices Offered and Type of Cell Line Sterility / Biosafety Testing Services Offered
Table 9.4 Cell line Characterization Service Providers: Information on Regulatory ComplianceRegulatoryAccreditations /Certifications Overall Turnaround Time, and Availability Of Additional Cell Line Related Services
Table 9.5 Cell Line Characterization: List of Service Providers (Non-Industry Players)
Table 9.6 Cell Line Characterization Service Providers: Information on Type Of Cell LineCharacterizationServiceOffered andTypeofGenotyping Services Offered
Table 9.7 Cell Line Characterization Service Providers: Information on Genotyping Kit Used,NumberofLociAmplified,ServiceChargesandOverall Turnaround Time
Table 11.1 Cell Line Characterization Service Providers: List of Companies Profiled
Table 11.2 Charles River Laboratories: Company Snapshot
Table 11.3 Charles River laboratories: Cell Line Characterization Service Portfolio
Table 11.4 Charles River Laboratories: Recent Developments and Future Outlook
Table 11.5 Eurofins BioPharma Product Testing: Company Snapshot
Table 11.6 Eurofins BioPharma Product Testing: Cell Line Characterization Service Portfolio
Table 11.7 Eurofins BioPharma Product Testing: Recent Developments and Future Outlook
Table 11.8 Livogen Pharmed: Company Snapshot
Table 11.9 Livogen Pharmed: Cell Line Characterization Service Portfolio
Table 11.10 Molecular Diagnostic Services: Company Snapshot
Table 11.11 Molecular Diagnostic Services: Cell Line Characterization Service Portfolio
Table 11.12 Sartorius: Company Snapshot
Table 11.13 Sartorius: Cell Line Characterization Service Portfolio
Table 11.14 Sartorius: Recent Developments and Future Outlook
Table 11.15 TFBS Bioscience: Company Snapshot
Table 11.16 TFBS Bioscience: Cell Line Characterization Service Portfolio
Table 11.17 TFBS Bioscience: Recent Developments and Future Outlook
Table 11.18 ATZ Labs: Company Snapshot
Table 11.19 ATZ Labs: Cell Line Characterization Service Portfolio
Table 11.20 Avance Biosciences: Company Snapshot
Table 11.21 Avance Biosciences: Cell Line Characterization Service Portfolio
Table 11.22 BioReliance: Company Snapshot
Table 11.23 BioReliance: Cell Line Characterization Service Portfolio
Table 11.24 Clean Cells: Company Snapshot
Table 11.25 Clean Cells: Cell Line Characterization Service Portfolio
Table 11.26 Hylabs: Company Snapshot
Table 11.27 Hylabs: Cell Line Characterization Service Portfolio
Table 11.28 Samsung Biologics: Company Snapshot
Table 11.29 Samsung Biologics: Cell Line Characterization Service Portfolio
Table 11.30 SGS Life Sciences: Company Snapshot
Table 11.31 SGS Life Sciences: Cell Line Characterization Service Portfolio
Table 11.32 Texcell: Company Snapshot
Table 11.33 Texcell: Cell Line Characterization Service Portfolio
Table 11.33 WuXi Advanced Therapies: Company Snapshot
Table 11.35 WuXi Advanced Therapies: Cell Line Characterization Service Portfolio
Table 12.1. Cell Line Development and Characterization: List of Partnerships and Collaborations,2019-2023
Table 13.1 Cell Line Development and Characterization Services: List of Recent Expansions, 2019-2023
Table 15.1 List of Journals with Mandatory Requirement of Cell Line Authentication for ResearchSubmissions
Table 15.2 International Cell Line Authentication Committee (ICLAC): Partner Organizations
Table 15.3 WHO Recommendations: Cell Bank Characterization
Table 15.4 Regulatory Documents for Cell Line Characterization in the US
Table 15.5 US Pharmacopoeia (USP) 1050: Virus Testing in Cell Banks
Table 15.6 European Pharmacopoeias: Testing in Cell Banks
Table 28.1 Biofortuna: Company Snapshot
Table 28.2 Abgenex: Company Snapshot
Table 28.3 GTP Bioways: Company Snapshot
Table 28.4 QuaCell Biotechnology: Company Snapshot
Table 28.5 Laragen: Company Snapshot
Table 28.6 Polpharma Biologics: Company Snapshot
Table 28.7 LakePharam (Acquired by Curia): Company Snapshot
Table 28.8 ARTES Biotechnology: Company Snapshot
Table 28.9 ImmunoPrecise Antibodies (Formerly Modiquest): Company Snapshot
Table 28.10 Polpharma Biologics: Company Snapshot
Table 29.1 Cell Line Development Service Providers: Distribution by Year of Establishment
Table 29.2 Cell Line Development Service Providers: Distribution by Company Size
Table 29.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
Table 29.4 Cell Line Development Service Providers: Distribution by Company Size and Location ofHeadquarters
Table 29.5 Cell Line Development Service Providers: Distribution by Source of Cell Line / Expression System Offered
Table 29.6 Cell Line Development Service Providers: Distribution by Gene Delivery Method Used
Table 29.7 Cell Line Development Service Providers: Distribution by Type of Transfection
Table 29.8 Cell Line Development Service Providers: Distribution by Availability of Serum-Free /Animal Component Free Culturing Capability
Table 29.9 Cell Line Development Service Providers: Distribution by Type of Cells Offered
Table 29.10 Cell Line Development Service Providers: Distribution by Application of Cell Lines
Table 29.11 Cell Line Development Service Providers: Distribution by Additional Cell Line Related Services Offered
Table 29.12 Cell Line Development Service Providers: Distribution by Type of Cell Banking
Table 29.13 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
Table 29.14 Cell Line Characterization Service Providers: Overall Market Landscape
Table 29.15 Cell Line Characterization Service Providers (Industry): Distribution by Year of Establishment
Table 29.16 Cell Line Characterization Service Providers (Industry): Distribution by Company Size
Table 29.17 Cell Line Characterization Service Providers (Industry): Distribution by Location of Headquarters
Table 29.18 Cell Line Characterization Service Providers (Industry): Distribution by Company Size and Location of Headquarters
Table 29.19 Cell Line Characterization Service Providers (Industry): Distribution by Cell Line Characterized
Table 29.20 Cell Line Characterization Service Providers (Industry): Distribution by Type of Cell Line Characterization Services Offered
Table 29.21 Cell Line Characterization Service Providers (Industry): Distribution by Type of Cell Line Identity / Stability TestingService Offered
Table 29.22 Cell Line Characterization Service Providers (Industry): Distribution by Type of Cell Line Sterility / Biosafety Testing Service Offered
Table 29.23 Cell Line Characterization Service Providers (Non-Industry): Distribution by Location of Organization
Table 29.24 Cell Line Characterization Service Providers (Non-Industry): Distribution by Type of Cell Line Characterized
Table 29.25 Cell Line Characterization Service Providers (Non-Industry): Distribution by Type of Cell Line Characterization ServiceOffered
Table 29.26 Cell Line Characterization Service Providers (Non-Industry): Distribution by Genotyping Kit Used
Table 29.27 Cell Line Characterization Service Providers (Non-Industry): Distribution by Number of Loci Amplified
Table 29.28 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2023
Table 29.29 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.30 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 29.31 Partnerships and Collaborations: Distribution by Type of Partner
Table 29.32 Most Active Players: Distribution by Number of Partnerships
Table 29.33 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
Table 29.34 Partnerships and Collaborations: Local and International Deals
Table 29.34 Recent Expansions: Cumulative Year-wise Trend, -2023
Table 29.36 Recent Expansions: Distribution by Type of Expansion
Table 29.37 Recent Expansions: Distribution by Year and Type of Expansion
Table 29.38 Recent Expansions: Distribution by Location of Headquarters and Company Size
Table 29.39 Recent Expansions: Distribution by Location of Expanded Facility
Table 29.40 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 29.41 Recent Expansions: Distribution by Area of Expanded Facility (sq. ft.)
Table 29.42 Recent Expansions: Distribution by Purpose of Expansion
Table 29.43 Recent Expansions: Analysis by Geography
Table 29.44 Most Active Players: Distribution by Number of Recent Expansions
Table 29.45 Global Cell Line Development Services Market, Historical Trends (2019-2022) (USD Million)
Table 29.46 Global Cell Line Development Services Market, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario(USD Million)
Table 29.47 Cell Line Development Services Market: Distribution by Source of Cell Line 2019, 2023 and 2035 (USD Million)
Table 29.48 Cell Line Development Services Market for Mammalian Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.49 Cell Line Development Services Market for Mammalian Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.50 Cell Line Development Services Market for Microbial Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.51 Cell Line Development Services Market for Microbial Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.52 Cell Line Development Services Market for Insect Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.53 Cell Line Development Services Market for Insect Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.54 Cell Line Development Services Market for Other Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.55 Cell Line Development Services Market for Other Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.56 Cell Line Development Services Market: Distribution by Application of Cell Line 2019, 2023 and 2035 (USD Million)
Table 29.57 Cell Line Development Services Market for Biomanufacturing: Historical Trends (2019-2022) (USD Million)
Table 29.58 Cell Line Development Services Market for Biomanufacturing: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.59 Cell Line Development Services Market for Research and Development Operations: Historical Trends (2019-2022) (USD Million)
Table 29.60 Cell Line Development Services Market for Research and Development Operations: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.61 Cell Line Development Services Market: Distribution by Company Size 2019, 2023 and 2035 (USD Million)
Table 29.62 Cell Line Development Services Market for Large Companies: Historical Trends (2019-2022) (USD Million)
Table 29.63 Cell Line Development Services Market for Large Companies: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.64 Cell Line Development Services Market for Mid-Size Companies: Historical Trends (2019-2022) (USD Million)
Table 29.65 Cell Line Development Services Market for Mid-sized Companies: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.66 Cell Line Development Services Market for Small Companies: Historical Trends (2019-2022) (USD Million)
Table 29.67 Cell Line Development Services Market for Small Companies: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.68 Cell Line Development Services Market: Distribution by Key Geographical Regions 2019, 2023 and 2035 (USD Million)
Table 29.69 Cell Line Development Services Market for North America: Historical Trends (2019-2022) (USD Million)
Table 29.70 Cell Line Development Services Market for North America: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.71 Cell Line Development Services Market for Europe: Historical Trends (2019-2022) (USD Million)
Table 29.72 Cell Line Development Services Market for Europe: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.73 Cell Line Development Services Market for Asia-Pacific and Rest of the World: Historical Trends (2019-2022) (USD Million)
Table 29.74 Cell Line Development Services Market for Asia-Pacific and Rest of the World: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.75 Global Cell Line Characterization Services Market, Historical Trends (2019-2022) (USD Million)
Table 29.76 Global Cell Line Characterization Services Market, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.77 Cell Line Characterization Services Market: Distribution by Source of Cell Line 2019, 2023 and 2035 (USD Million)
Table 29.78 Cell Line Characterization Services Market for Mammalian Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.79 Cell Line Characterization Services Market for Mammalian Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.80 Cell Line Characterization Services Market for Microbial Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.81 Cell Line Characterization Services Market for Microbial Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.82 Cell Line Characterization Services Market for Insect Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.83 Cell Line Characterization Services Market for Insect Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.84 Cell Line Characterization Services Market for Other Cell Lines: Historical Trends (2019-2022) (USD Million)
Table 29.85 Cell Line Characterization Services Market for Other Cell Lines: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.86 Cell Line Characterization Services Market: Distribution by Application of Cell Line 2019, 2023 and 2035 (USD Million)
Table 29.87 Cell Line Characterization Services Market for Biomanufacturing: Historical Trends (2019-2022) (USD Million)
Table 29.88 Cell Line Characterization Services Market for Biomanufacturing: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.89 Cell Line Characterization Services Market for Research and Development Operations: Historical Trends (2019-2022) (USD Million)
Table 29.90 Cell Line Characterization Services Market for Research and Development Operations: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.91 Cell Line Characterization Services Market: Distribution by Company Size 2019, 2023 and 2035 (USD Million)
Table 29.92 Cell Line Characterization Services Market for Large Companies: Historical Trends (2019-2022) (USD Million)
Table 29.93 Cell Line Characterization Services Market for Large Companies: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.94 Cell Line Characterization Services Market for Mid-Size Companies: Historical Trends (2019-2022) (USD Million)
Table 29.95 Cell Line Characterization Services Market for Mid-sized Companies: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.96 Cell Line Characterization Services Market for Small Companies: Historical Trends (2019-2022) (USD Million)
Table 29.97 Cell Line Characterization Services Market for Small Companies: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.98 Cell Line Characterization Services Market: Distribution by Key Geographical Regions 2019, 2023 and 2035 (USD Million)
Table 29.99 Cell Line Characterization Services Market for North America: Historical Trends (2019-2022) (USD Million)
Table 29.100 Cell Line Characterization Services Market for North America: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.101 Cell Line Characterization Services Market for Europe: Historical Trends (2019-2022) (USD Million)
Table 29.102 Cell Line Characterization Services Market for Europe: Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 29.103 Cell Line Characterization Services Market for Asia-PacificandRestoftheWorld:HistoricalTrends (2019-2022) (USD Million)
Table 29.104 Cell Line Characterization Services Market for Asia-PacificandRestoftheWorld:ForecastedEstimates (2023-2035), Conservative,BaseandOptimisticScenario(USDMillion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report

  1. 10x Genomics
  2. 3P Biopharmaceuticals
  3. 53Biologics
  4. Aarhus University Hospital
  5. AbbVie
  6. Abcam
  7. Abclonal
  8. Abcuro
  9. Abdi Ibrahim Pharmaceuticals
  10. Abeomics
  11. ABGENEX
  12. ABL Bio
  13. Abnova
  14. Absci
  15. Abzena
  16. Acambis
  17. AcceGen
  18. Accuprec Research Labs
  19. Accurus Biosciences
  20. ACE Biolabs
  21. ACROBiosystems
  22. ACYTE Biotech
  23. AdaptVac
  24. AddexBio Technologies
  25. Adimmune
  26. Advanced Biomart
  27. Advanced Instruments
  28. A-Frontier
  29. AGC Biologics
  30. Agenus
  31. Akers Biosciences
  32. Akshaya Bio
  33. Albert Ludwigs University of Freiburg
  34. Aldevron
  35. Alira Health
  36. Almirall
  37. Alpha Lifetech
  38. ALS Automated Lab Solutions
  39. ALSTEM
  40. Altogen Labs
  41. Alvotech
  42. American Type Culture Collection
  43. Ampersand Capital Partners
  44. AMS Biotechnology
  45. Analytical Biological Services
  46. Analytical Lab Group
  47. ANLBIO
  48. Anthem Biosciences
  49. Applied Biological Materials (abm)
  50. Applied Genetics Laboratories
  51. APRINOIA Therapeutics
  52. Aragen Life Sciences
  53. Aravive
  54. Artes Biotechnology
  55. ArtiaBio
  56. Asahi Kasei
  57. Asahi Kasei Medical
  58. AscentGene
  59. Asher Biotherapeutics
  60. AstraZeneca
  61. Asymchem
  62. AtaGenix Laboratories
  63. Attana
  64. ATUM
  65. ATZ labs (a subsidiary of Life Technologies)
  66. Aurigene Pharmaceutical Services
  67. Australian Genome Research Facility
  68. Austrianova
  69. Avacta
  70. Avance Biosciences
  71. Avid Bioservices
  72. Azenta Life Sciences
  73. BaseClear
  74. Batavia Biosciences
  75. Bavarian Nordic
  76. Bayer
  77. Beacon Discovery
  78. Berkeley Lights
  79. Bex CO
  80. Bharat Biotech
  81. Bhat Bio-tech India
  82. BIBITEC 
  83. BICO
  84. BioAzure Technologies
  85. BIO-ENGINEERING
  86. BioFactura
  87. Biofortuna
  88. BioIngenium
  89. Biointron Biological
  90. BioInvenu
  91. Biologics International
  92. BioMax Lab
  93. Bioneer
  94. Bionique Testing Laboratories
  95. Bionova Scientific
  96. BioReliance
  97. Biosettia
  98. Bio-Synthesis
  99. BioTickle
  100. Biovian
  101. BioXpress Therapeutics
  102. BJ Bioscience
  103. BMR Genomics
  104. Boehringer Ingelheim
  105. Boehringer Ingelheim BioXcellence
  106. Bora Pharmaceuticals
  107. Boston Institute of Biotechnology
  108. BPS Bioscience
  109. Broad Institute of MIT and Harvard
  110. Bruker
  111. C&M Biolabs
  112. CALIXAR
  113. CANbridge Pharmaceuticals
  114. Canopy BioSciences
  115. Canton Biologics
  116. Capital Biosciences
  117. Carterra
  118. Case Western Reserve University
  119. Catalent Pharma Solutions
  120. Cell-Culture.Info
  121. Cell Guidance Systems
  122. Cell Line Genetics
  123. Cellaria
  124. CellBank Australia
  125. Cellero
  126. CellKraft Biotech
  127. Cellomics Technology
  128. Cells Online
  129. CellSafe
  130. Celltheon
  131. Celltrio
  132. Cellumed
  133. Cellutron Life Technologies
  134. Celonic
  135. Celplor
  136. Celther Polska
  137. Cerbios-Pharma
  138. Ceva Santé Animale
  139. CEVEC Pharmaceuticals
  140. Charles River Laboratories
  141. ChemPartner
  142. Children's Medical Research Institute
  143. Chitose Laboratory
  144. ChoA Pharmaceutical
  145. Cipla
  146. City of Hope
  147. CJ CheilJedang
  148. Clean Cells (a part of Clean Biologics)
  149. Cleveland Clinic Lerner Research Institute
  150. Clongen Laboratories
  151. CLS Cell Lines Service
  152. CMAB Biopharma
  153. CORE Diagnostics
  154. Coriell Institute for Medical Research
  155. Cosmogenetech
  156. Creative Bioarray
  157. Creative Biogene
  158. Creative Biolabs
  159. Creative BioMart
  160. Creative Peptides
  161. Crown Bioscience
  162. CSL Behring
  163. Culture Biosciences
  164. CureVac
  165. Curia
  166. Cypre
  167. Cytena
  168. Cytiva
  169. Cytovance Biologics
  170. Dana Farber Cancer Institute
  171. DC3 Therapeutics
  172. Detai Bioscience
  173. Diagnostic Cytogenetics
  174. DINONA
  175. DKSH
  176. DNA Forensics Laboratory
  177. DNA Labs India
  178. Duke University School of Medicine
  179. DYNAMIMED
  180. Early Drug Development Group (E2DG)
  181. EirGenix
  182. Elabscience
  183. Element Materials Technology
  184. Eminence Biotechnology
  185. EMP Genetech
  186. Enzolytics
  187. EpiGex
  188. ERS Genomics
  189. Esco Aster
  190. Eton Bioscience
  191. EuBiologics
  192. EUGENEX Biotechnologies
  193. Eurofins BioPharma Product Testing
  194. Eurofins Discovery
  195. Eurofins Genomics
  196. European Collection of Authenticated Cell Cultures
  197. EuroscreenFAST
  198. Eutilex
  199. Evercyte
  200. Evotec
  201. Evox Therapeutics
  202. ExcellGene
  203. ExpreS2ion Biotechnologies
  204. Extherid Biosciences
  205. Fapon Biotech
  206. Feinberg School of Medicine, Northwestern University
  207. First BASE Laboratories
  208. FlowMetric
  209. Fondazione Telethon
  210. Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB
  211. Fraunhofer Institute for Molecular Biology and Applied Ecology IME
  212. Fuji Pharma
  213. FUJIFILM Diosynth Biotechnologies
  214. Fusion Antibodies
  215. FyoniBio
  216. G&P Biosciences
  217. Garvan Institute of Medical Research
  218. GeneBeyond
  219. GeneCopoeia
  220. Genedata
  221. GENENMED
  222. Generi Biotech
  223. GENERIUM
  224. Genetica DNA Laboratories
  225. GENEWIZ
  226. Genexplore Diagnostics and Research Centre
  227. GenomeScan
  228. Genovis
  229. genOway
  230. GenScript
  231. GenScript Biotech
  232. GenScript ProBio
  233. GenTarget
  234. GeoVax Labs
  235. German Cancer Research Center
  236. German Collection of Microorganisms and Cell Cultures
  237. GI Innovation
  238. GlaxoSmithKline
  239. Granada Junta de Andalucía Center for Genomics and Oncological Research (GENYO)
  240. Granite Bio
  241. Griffith University
  242. GT Biopharma
  243. GTP Bioways
  244. GTP Technology
  245. GVK BIO
  246. Harbour BioMed
  247. Harvest Moon Pharmaceuticals
  248. Heidelberg Pharma
  249. HemaCare
  250. Hera BioLabs
  251. Horizon Discovery
  252. Hospital for Sick Children
  253. Humanigen
  254. Huons
  255. Hylabs
  256. Hyprocell
  257. Icosagen (formerly Quattromed)
  258. IDEXX Laboratories
  259. IGM Biosciences
  260. Igyxos Biotherapeutics
  261. IMGENEX INDIA
  262. ImmuneOncia Therapeutics
  263. ImmunoGenesis
  264. ImmunoPrecise Antibodies
  265. Immunostep
  266. Imvaq Therapeutics
  267. InnoBation
  268. Innovent
  269. InSCREENeX
  270. Institut für Forensische Genetik
  271. Institute of Department of Biotechnology
  272. Intravacc
  273. InVivo BioTech (a Bruker company)
  274. Iovance Biotherapeutics
  275. iTolerance
  276. JAMP Pharma
  277. Janssen
  278. Jefferson Institute for Bioprocessing
  279. Jenner Institute
  280. JHL Biotech
  281. Johns Hopkins University
  282. JSR Life Sciences
  283. Junshi Biosciences
  284. KAHR Medical
  285. Kanaph Therapeutics
  286. KangaBio
  287. KBI Biopharma
  288. KBio
  289. KBIO Health
  290. Kemp Proteins
  291. Kemwell Biopharma
  292. KMD Bioscience
  293. Krishgen Biosystems
  294. Labcorp
  295. Laekna Therapeutics
  296. LakePharma
  297. LamKap Bio
  298. Laragen
  299. Lava Therapeutics
  300. Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell Cultures
  301. LFB Biomanufacturing
  302. Limin International Group
  303. LinKinVax
  304. Lipum
  305. Livogen Pharmed
  306. Lonza
  307. LOTTE BIOLOGICS
  308. Luminex
  309. Mabion
  310. MabPlex International
  311. Mammoth Biosciences
  312. MassBiologics
  313. MaSTherCell
  314. Matica Biotechnology
  315. MDimune
  316. MEMO Therapeutics
  317. Merck
  318. MGC Pharma (a subsidiary of Mitsubishi Gas Chemical company)
  319. Microsynth
  320. Midas Pharma
  321. MilliporeSigma
  322. Minerva Analytix
  323. Mithra Biotechnology
  324. Molecular Cloning Laboratories (MCLAB)
  325. Molecular Diagnostic Services
  326. Molecular Medicine
  327. Monopar Therapeutics
  328. Moredun Scientific
  329. Mount Sinai Health System
  330. Multiplexion
  331. Multispan
  332. Mycenax Biotech
  333. Mycoplasma Experience
  334. NAMSA
  335. Nanoscope Therapeutics
  336. National Biologics Facility
  337. National Centre For Cell Science
  338. Navrogen
  339. NextPoint Therapeutics
  340. NGM Biopharmaceuticals
  341. NightHawk Biosciences
  342. Noachis Terra
  343. Nobelpharma
  344. NorClone Biotech Laboratories
  345. Nordmark Biotech
  346. North Star Medical Radioisotopes
  347. Northway Biotech
  348. Novartis
  349. Novatein Biosciences
  350. Nucleome Informatics
  351. Oak BioSciences
  352. Okmed Biotech
  353. Ology Bioservices
  354. Oncodesign
  355. OncoOne
  356. OneWorld Biotech
  357. Ono pharmaceuticals
  358. OPM Biosciences
  359. Oragenics
  360. Oregon Health & Science University
  361. OriGene
  362. Oxford Expression Technologies
  363. Oxford Nanopore Technologies
  364. Oxford University
  365. OXGENE (a WuXi Advanced Therapies company)
  366. PanGen Biotech
  367. Panolos Bioscience
  368. Paragon Bioservices
  369. Paraza Pharma
  370. Patheon
  371. PathoQuest
  372. Perfectus Biomed
  373. PerkinElmer
  374. Pfizer
  375. Phanes Therapeutics
  376. PharmAbcine
  377. Pharmaron
  378. PhaseBio Pharmaceuticals
  379. PhenomeX (acquired by Bruker)
  380. Phenotypeca
  381. Phylex Biosciences
  382. Polpharma Biologics
  383. POLYGON Therapeutics
  384. Polymun Scientific
  385. Porton Biologics
  386. Precision Antibody
  387. Premas Biotech
  388. Prestige BioPharma
  389. ProBioGen
  390. Profacgen
  391. ProMab Biotechnologies
  392. Promega
  393. PROMISE Proteomics
  394. Protein Sciences
  395. Protein Technologies
  396. ProteinCT Biotech
  397. ProteoCell Biotechnologies
  398. Proteogenix
  399. ProteoNic
  400. PX'Therapeutics
  401. QED Bioscience
  402. qGenomics
  403. QIMR Berghofer Medical Research Institute
  404. QuaCell Biotechnology
  405. Queen’s University Belfast
  406. Rajiv Gandhi Centre for Biotechnology
  407. RayBiotech
  408. RCC Laboratories
  409. RD-BIOTECH
  410. Recipharm
  411. ReliaTech
  412. Remedium Bio
  413. Rentschler Biopharma
  414. Resilience
  415. Revolo Biotherapeutics
  416. RheinCell Therapeutics
  417. Richter-Helm BioLogics
  418. RIKEN BioResource Center
  419. Roche
  420. Rockland Immunochemicals
  421. Rodon Biologics
  422. Roswell Park Comprehensive Cancer Center
  423. SAL Scientific
  424. Samsung Biologics
  425. Sandoz
  426. Sanford Burnham Prebys Medical Discovery Institute
  427. Sanofi Pasteur
  428. Sanyou Biopharmaceuticals
  429. Sartorius
  430. Sartorius Stedim Cellca
  431. SB Drug Discovery
  432. SecuGen
  433. Selecxine
  434. Selexis
  435. Seqirus
  436. SeQure Dx
  437. Serum Institute of India
  438. SGS Life Sciences
  439. Shanghai Biowing Applied Biotechnology
  440. Shanghai Medicilon
  441. Shanghai Optima Biotechnology
  442. Shire (acquired by Takeda)
  443. SIB Swiss Institute of Bioinformatics
  444. Sigma-Aldrich
  445. Signosis
  446. Sino Biological
  447. Sinorda BIomedicine
  448. Six.02 Bioservices
  449. Solentim
  450. Speed BioSystems
  451. Sphere Fluidics
  452. Spicona
  453. SpyBiotech
  454. STADA Arzneimittel
  455. Stanford University
  456. Statens Serum Institut
  457. STC Biologics
  458. STCube
  459. Stellixir Biotech
  460. Strike Pharma
  461. Summit Pharmaceuticals International (SPI)
  462. Sundia MediTech
  463. Svar Life Science
  464. SwissLumix
  465. Syd Labs
  466. Sygnature Discovery
  467. Syngene International
  468. System Biosciences
  469. Tamil Nadu Veterinary and Animal Sciences University (TANUVAS)
  470. TCG Lifesciences
  471. Tebubio
  472. Technion Israel Institute of Technology
  473. Telesis Bio
  474. TeneoBio
  475. TentaMedix
  476. Teva Pharmaceuticals
  477. Texcell
  478. TFBS Bioscience
  479. The Centre for Applied Genomics
  480. The Human Protein Atlas
  481. The Native Antigen
  482. Thermo Fisher Scientific
  483. Toleranzia
  484. Toregem Bio Pharma
  485. Tosoh Bioscience
  486. TPG Biologics
  487. Transposagen Biopharmaceuticals
  488. TransViragen
  489. Trenzyme
  490. Trinomab Biotech
  491. TrioBio
  492. TrueBinding
  493. Tulane University
  494. Turgut Pharmaceuticals
  495. TWIN HELIX
  496. Twist Bioscience
  497. UGA Biopharma
  498. UNC School of Medicine
  499. United BioLabs
  500. University At Albany
  501. University College London
  502. University of Arizona
  503. University of California
  504. University of Cambridge
  505. University of Colorado Anschutz Medical Campus
  506. University of Connecticut
  507. University of Edinburgh
  508. University of Florida
  509. University of Helsinki
  510. University of Illinois
  511. University of Manchester
  512. University of Pennsylvania
  513. University of Sussex
  514. University of Sydney
  515. University of Technology, Sydney
  516. University of Texas
  517. University of Utah
  518. University of Vermont
  519. University of Warsaw
  520. University of Wisconsin
  521. UT Southwestern Medical Center
  522. Vaccitech
  523. ValenzaBio (acquired by ACELYRIN)
  524. Vall d'Hebron Research Institute
  525. Valneva Austria
  526. Vanderbilt University Medical Center
  527. VectorBuilder
  528. Vectron Biosolutions
  529. VelaLabs
  530. Veterinary Medical Research & Development
  531. Vibalogics 
  532. Vir Biotechnology
  533. Virongy
  534. ViruSure
  535. Vista Biologicals
  536. VVector Bio
  537. W. L. Gore & Associates
  538. WACKER Biotech
  539. Waisman Biomanufacturing
  540. WatsonBio Sciences
  541. Welgen
  542. Westmead Institute for Medical Research
  543. Wheeler Bio
  544. WiCell
  545. Wuhan Dian Biotechnology
  546. WuXi Advanced Therapies
  547. WuXi Biologics
  548. Wyndham Forensic Group
  549. Xell
  550. XL-protein
  551. Yale School of Medicine
  552. Zellkraftwerk
  553. Zhejiang University
  554. ZyVersa Therapeut

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com